Puma Biotechnology Inc Stock News

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemothe

Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.

Gainers Peak Bio, Inc. (NASDAQ: PKBO) shares surged 105.8% to close at $7.82 on Friday. Peak Bio reported closing of up to $100 million common stock purchase transaction with White Lion Capital. Lade

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Mariann Ohanesian - Investor Relations Alan Auerbach - Chief Executive Officer

Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United S

Puma Biotech (PBYI) delivered earnings and revenue surprises of 90.91% and 11.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.

Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.

Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.